Plasma ceramides are a class of lipids that are highly linked to cardiovascular disease processes. Mayo Clinic has launched a new type of blood test that will measures blood concentrations of plasma ceramides to predict adverse cardiovascular events in patients with progressing coronary artery disease (CAD).
Researchers say this test is especially useful for patients with CAD when it does not improve with treatment or for young patients with premature CAD.
‘A new blood test will measures blood concentrations of plasma ceramides to predict adverse cardiovascular events in patients with progressing coronary artery disease (CAD). ’
AdvertisementThe new test will help clinicians identify at-risk individuals and is available to Mayo Clinic patients and health care providers worldwide through Mayo Medical Laboratories (MML). MML is the reference laboratory of Mayo Clinic, offering advanced laboratory testing and pathology services to more than 5,000 health care organizations in more than 60 countries. MML collaborated on the test with Zora Biosciences Oy, a diagnostics discovery company based in Finland that specializes in cardiovascular disease.
"Through our strong collaboration with Zora Biosciences, we hope our new test will improve the evaluation of individuals at risk for cardiovascular disease," says Jeff Meeusen, a clinical chemist and co director of Cardiovascular Laboratory Medicine at Mayo Clinic. "This test is for patients with highly specialized cases, for example, patients with progressing coronary artery disease - despite treatment and control of their risk factors, or for younger individuals with premature CAD."
The test also might be used to determine if treatment is necessary in individuals at intermediate risk via the risk calculator from the American College of Cardiology and the American Heart Association.
"Plasma ceramides are promising biomarkers for the prediction of adverse CV events in either primary and/or secondary prevention. The studies to date suggest that the signals observed presage events within the next five-year period," says Allan Jaffe, cardiologist at Mayo Clinic and chair of the Division of Clinical Core Laboratory Services, with joint appointments in the Department of Cardiovascular Diseases and the Department of Laboratory Medicine and Pathology. "Risk conferred by plasma ceramides appears to be independent of other established and novel biomarkers, and there are preliminary indications that high ceramide concentrations can be modified by common lipid-lowering therapies."